A Novel Immune-Related Prognostic Model for Response to Immunotherapy and Survival in Patients With Lung Adenocarcinoma

Lung adenocarcinoma is one of the most malignant diseases worldwide. The immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) have changed the paradigm of lung cancer treatment; however, there are still patients who are resistant. F...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yujia, Tian, He, Zhou, Zheng, Xiao, Chu, Liu, Hengchang, Liu, Yu, Wang, Liyu, Fan, Tao, Zheng, Bo, Tan, Fengwei, Xue, Qi, Gao, Gengshu, Li, Chunxiang, He, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017122/
https://www.ncbi.nlm.nih.gov/pubmed/33816503
http://dx.doi.org/10.3389/fcell.2021.651406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017122/
https://www.ncbi.nlm.nih.gov/pubmed/33816503
http://dx.doi.org/10.3389/fcell.2021.651406

Ejemplares similares